Connect with us

Medical Research

New Study: Nationwide Opioid Prescription Rates Lower with Cannabis Legalization, Colorado Leads the Way

Published

on

New Study: Nationwide Opioid Prescription Rates Lower with Cannabis Legalization, Colorado Leads the Way

Researchers from the Geisinger Commonwealth School of Medicine and the University of New England recently conducted a study to better understand how legalizing marijuana has affected other prescription drugs for pain management. The study concluded that since marijuana legalization, there has been a significant reduction in opioid prescriptions for pain management reports Marijuana Moment.

For the purpose of the study, Colorado was compared to Maryland and Utah. The latter two were chosen because they too were one of the firsts to legalize cannabis, and were demographically and geographically similar respectively.

In conclusion

“Colorado has had a larger decrease in opioid distribution after 2012 than Utah or Maryland. Therefore, marijuana could be considered as an alternative treatment for chronic pain and reducing use of opioids.”

The rate at which prescription drugs were handed out was monitored between a 10-year time span (2007 to 2010), where the data – which assesses nine to eleven different types of drugs for pain – was obtained from the Drug Enforcement Administration.

To ensure that the drugs can be comparable among each other, the amount of each drug was converted so that it would be equal to a dose of oral morphine in milligrams (MME).

Here are some of the highlights of the study that have been pointed out:

  • The weight of 11 opioids hit 12,167 kg MME in Maryland, two times more than Colorado’s (5,029 kg MME) and Utah’s (3,249 kg MME)
  • All three states’ common drugs distribution includes oxycodone and methadone
  • 31% cut in Utah’s methadone and buprenorphine prescriptions, while Colorado (+19%) and Maryland (67%) saw an increase
  • Colorado sees 12% decrease in prescription drugs amidst marijuana legalization, while Utah sees 10% increase and Maryland sees 6% decrease

Given such significant results, it supposedly remains unclear as to why there was a decrease in prescription drugs, stressing that many factors could have played a role.

As referenced from the study:

“Colorado and Maryland experienced an overall decrease in opioid distribution, but Colorado’s decrease was larger. While the nation as a whole was experiencing a decrease in opioid distribution, it was promising that Colorado’s greater decrease gives consideration to the potential impact of recreational marijuana.”

That said, the team behind the study trusts it’s now time to discharge patients from “pain treatment centers” and to consider marijuana for not only pain management, but also possibly to “reduce their overall opioid use.”

George deGeyter is a professional Canadian writer with over a decade of experience getting his start in 2007 while obtaining his bachelor’s degree in accounting and humanities. Boasting a personal library of hundreds of books on a wide range of topics, George loves to write on a vast array of topics including health, technology, pets, beauty, gardening, business careers and has added CBD and hemp to his repertoire here at TOC.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.